Hepatic CREBZF couples insulin to lipogenesis by inhibiting insig activity and contributes to hepatic steatosis in diet‐induced insulin‐resistant mice

Feifei Zhang, Zhimin Hu, Gaopeng Li, Shaofeng Huo, Fengguang Ma, Aoyuan Cui, Yaqian Xue, Yamei Han, Qi Gong, Jing Gao, Hua Bian, Zhuoxian Meng, Haifu Wu, Gang Long, Yi Tan, Yan Zhang, Xu Lin, Xin Gao, Aimin Xu, Yu Li – 10 April 2018 – Insulin is critical for the regulation of de novo fatty acid synthesis, which converts glucose to lipid in the liver. However, how insulin signals are transduced into the cell and then regulate lipogenesis remains to be fully understood.

Cost‐effectiveness of antiviral treatment after resection in hepatitis B virus–related hepatocellular carcinoma patients with compensated cirrhosis

Li Xie, Juan Yin, Ruyi Xia, Guihua Zhuang – 7 April 2018 – Hepatocellular carcinoma (HCC) imposes a heavy disease burden on China due to its high morbidity and mortality. China accounts for about 50% of the total new cases and deaths worldwide. Most cases are related to hepatitis B virus (HBV) infection and are associated with cirrhosis at diagnosis. Antiviral treatment with nucleos(t)ide analogues (NAs) after resection in HBV‐related HCC can reduce recurrence and improve survival. Such treatment is in fact recommended by Chinese guidelines.

Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis

Dirk J. van der Windt, Vikas Sud, Hongji Zhang, Patrick R. Varley, Julie Goswami, Hamza O. Yazdani, Samer Tohme, Patricia Loughran, Robert M. O'Doherty, Marta I. Minervini, Hai Huang, Richard L. Simmons, Allan Tsung – 6 April 2018 – Nonalcoholic steatohepatitis (NASH) is a progressive, inflammatory form of fatty liver disease. It is the most rapidly rising risk factor for the development of hepatocellular carcinoma (HCC), which can arise in NASH with or without cirrhosis. The inflammatory signals promoting the progression of NASH to HCC remain largely unknown.

Should organs from hepatitis C‐positive donors be used in hepatitis C‐negative recipients for liver transplantation?

Nazia Selzner, Marina Berenguer – 6 April 2018 – Given the scarcity of donated organs and the frequency of death on the waiting list, strategies that could improve the available supply of high‐quality liver grafts are much needed. Direct‐acting antiviral agent (DAA) regimens have proved to be highly effective to treat hepatitis C virus (HCV), even in the setting of posttransplantation. The question arises as to whether transplant communities should consider the utilization of HCV‐positive donors into HCV‐negative recipients.

Subscribe to